Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1810 results
September 2017
-
In The News
Novartis Access and government of Cameroon sign agreement to fight chronic diseases
Cameroon faces a serious increase in chronic diseases like heart disease, asthma, cancer and diabetes. This agreement complements the government’s ongoing efforts by improving access to affordable… -
Media Release
Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets
Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer New Novartis-Berkeley Center for Proteomics and… -
Media Release
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model GIPAP was introduced 15 years ago and has… -
Media Release
Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Significant overall survival benefit seen with Rydapt, the first targeted treatment for newly diagnosed FLT3-mutated AML approved in the EU[1] As the first and only therapy for advanced SM… -
Story Patient Perspectives
Led by Steven Taylor, the Sjögren’s Syndrome Foundation is raising awareness of a little-known autoimmune disease
-
Media Release
Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled[1] Should a treatment pause be necessary, data showed almost… -
Media Release
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile[1]Sandoz proposed biosimilar adalimumab is currently under… -
Media Release
Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
Cosentyx® (secukinumab) is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis[1] Landmark data show that PASI… -
Media Release
Sandoz proposed biosimilar rituximab accepted for review by the FDA
Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis[1] Sandoz believes the comprehensive data package submitted to the FDA for review confirms… -
Media Release
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all pre-specified… -
Media Release
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
AMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need Dedicated… -
In The News
Changing the world
Novartis was ranked 4th in Fortune magazine’s Change the World list and cited for developing an innovative new cancer treatment, working to expand access to healthcare and supporting value-based…